HISTORY & FOCUS
Brain Neurotherapy Bio, Inc (BrainNeuBio) was established in 2018 by Krystof S. Bankiewicz, MD, PhD in association with the founders of Asklepios Biotherapeutics (AskBio), Sheila Mikhail, JD, MBA and R. Jude Samulski, PhD.
BrainNeuBio is a startup biotechnology company that focuses on the development of preclinical and early stage clinical neurotrophic factor gene therapies and associated technologies for the treatment of Parkinson’s disease and other neurological conditions.
BrainNeuBio’s initial developmental focus is advancing the safety and establishing preliminary efficacy measures related to glial cell line-derived neurotrophic factor (GDNF) gene therapy for Parkinson’s disease. This program utilizes the clinically-proven AAV2 gene transfer platform, delivered within the brain via precise convection-enhanced delivery (CED) methods.